The Trump administration's push for lower U.S. drug prices inadvertently helped Astellas Pharma secure higher reimbursement pricing for its new eye medicine in Japan, suggesting a shift in Japanese government stance on drug pricing. Additionally, Novo Nordisk’s Wegovy obesity drug was found to have a significantly higher risk of ischemic optic neuropathy compared to other GLP-1 agonists like Ozempic, highlighting the need for content creators to stay informed about emerging health risks and regulatory changes when discussing pharmaceutical products.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
19
Comments
Ali NematiWritten by Ali
